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Loss-of-function mutations in the Autoimmune Regulator (AIRE) gene cause a rare inherited
form of autoimmune disease, autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy, also known as autoimmune polyglandular syndrome type 1. The patients suffer
from multiple endocrine deficiencies, the most common manifestations being hypoparathy-
roidism, Addison’s disease, hypogonadism, and secondary amenorrhea, usually accompa-
nied by typical autoantibodies against the target tissues. Chronic mucocutaneous candidi-
asis is also a prominent part of the disease. The highest expression of AIRE is found in
medullary thymic epithelial cells (mTECs). Murine studies suggest that it promotes ectopic
transcription of self antigens in mTECs and is thus important for negative selection. How-
ever, failed negative selection alone is not enough to explain key findings in human patients,
necessitating the search for alternative or additional pathogenetic mechanisms. A striking
feature of the human AIRE-deficient phenotype is that all patients develop high titers of
neutralizing autoantibodies against type I interferons, which have been shown to downreg-
ulate the expression of interferon-controlled genes. These autoantibodies often precede
clinical symptoms and other autoantibodies, suggesting that they are a reflection of the
pathogenetic process. Other cytokines are targeted as well, notably those produced by
Th17 cells; these autoantibodies have been linked to the defect in anti-candida defenses.
A defect in regulatoryT cells has also been reported in several studies and seems to affect
already the recent thymic emigrant population. Taken together, these findings in human
patients point to a widespread disruption of T cell development and regulation, which is
likely to have its origins in an abnormal thymic milieu. The absence of functional AIRE in
peripheral lymphoid tissues may also contribute to the pathogenesis of the disease.
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INTRODUCTION
Monogenic diseases, although rare, provide a unique possibil-
ity to obtain information in the human system on the signif-
icance and function of the molecules affected by the muta-
tions. Autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED), also known as autoimmune polyendocrine
syndrome type 1 (APS-1), is one such natural knockout pheno-
type, and has provided important information on T cell selection
and pathogenesis of organ-specific autoimmunity (1, 2). It is a
recessively inherited human autoimmune disease, caused by loss-
of-function mutations in the Autoimmune Regulator (AIRE) gene
(3, 4). It is enriched in certain populations, most notably the Finns
(prevalence 1:25 000), Sardinians (1:14 000), and Iranian Jews (1:9
000) (5). The pathognomonic triad consists of chronic candidia-
sis, hypoparathyroidism, and Addison’s disease, with several other
endocrine and non-endocrine manifestations affecting a smaller
fraction of the patients.
Abbreviations: AIRE, autoimmune regulator; ALAT, alanine amino transferase;
APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy;
APS-1, autoimmune polyendocrine syndrome type 1; CMC, chronic mucocuta-
neous candidiasis; GAD, glutamic acid decarboxylase; LKM, liver-kidney microso-
mal; mTEC, medullary thymic epithelial cells; RTE, recent thymic emigrant; TRA,
tissue-restricted antigen; Treg, regulatory T cell.
Since the discovery of the underlying genetic defect in 1997,
the pathogenesis of this rare polyendocrine syndrome has been
the focus of considerable interest. In particular, studies in Aire-
deficient mice have shown that AIRE plays an important role in
T cell development and negative selection in the thymus, thus
elucidating general pathways of thymic development (2). How-
ever, the murine phenotype differs in several key points from the
human disease, not least in the absence of all the defining triad
components mentioned above (6). It is clear that to understand
how AIRE works in the human immune system, the human dis-
ease mechanisms have to be studied on their own terms, and not
only as an extension of the murine phenotype. Such an approach
has already proved successful, for example by revealing the role
of anti-cytokine antibodies in causing the increased susceptibility
to Candida infections (7). Here, we review the main features of
human APECED, both clinical and immunological. Although sev-
eral important questions remain open, we also attempt to provide
an explanation of the pathogenetic mechanisms, looked at from
the human viewpoint.
CLINICAL FEATURES
The classic triad of APECED consists of Addison’s disease,
hypoparathyroidism, and chronic mucocutaneous candidiasis
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(CMC), two of which are required for the diagnosis. The autoim-
munity in APECED is organ-specific but with many components.
There is no gender bias. Virtually all patients have more than two
disease components and up to 10 components have been reported.
On the average patients have four components (8). First symp-
toms occur on average at the age of five (range 0.2–18 years) (9).
The most common endocrinopathies, hypoparathyroidism, and
Addison’s disease are usually diagnosed at the age of 3–5 years
and 11–15 years, respectively. New components appear through
life (9).
Chronic mucocutaneous candidiasis is usually the first sign of
APECED and in Finnish patients its prevalence is 100%. Can-
didiasis is the most common component of APECED except in
Iranian Jews in whom it is rarely described (10). The severity of
the symptoms varies from redness and soreness of the corners of
the mouth to inflamed mucosal surfaces in the whole oral cavity.
Candidiasis increases the risk of oral carcinoma by causing chronic
inflammation (1).
Hypoparathyroidism is the most common autoimmune com-
ponent in APECED and APECED should be considered in the
differential diagnosis of every patient with hypoparathyroidism
of unknown cause. Addison’s disease is the second most common
autoimmune component and its prevalence was 78% in a large
patient series (9). It most often presents with both mineralo- and
glucocorticoid deficiency. Gonadal failure is a common compo-
nent, especially in women. Ovarian insufficiency is actually the
third most common autoimmune component, affecting approxi-
mately 65% of APECED women and starting in early adulthood
(9). It can present with primary amenorrhea with a complete fail-
ure of or arrested pubertal development. About half of the cases
develop premature menopause (9). Testicular failure has a max-
imum prevalence of 25% in men and starts usually at an older
age (11).
About one third of APECED patients develop hypothyroidism,
usually after puberty (9). Thyroid autoantibodies are found com-
monly but clinical disease is not always present. The preva-
lence of type I diabetes mellitus among APECED patients varies
between populations. In a large Finnish patient series, the preva-
lence was about 30% (8). Gastrointestinal symptoms, such as
chronic diarrhea, constipation, hepatitis, and gastritis are com-
mon. Autoimmune gastritis with pernicious anemia is present in
approximately 30% of patients by middle age (9). In severe forms,
patients develop chronic atrophic gastritis and pernicious anemia
(9). About 20% of patients develop autoimmune hepatitis with
variable severity (8).
Ectodermal manifestations include enamel hypoplasia of the
teeth, alopecia, nail dystrophies, vitiligo, and ocular keratopathy
(8, 9). Keratitis occurs in 25% of the patients and can lead to
vision loss. Keratitis can be an early and even the first manifesta-
tion of the disease. Alopecia and vitiligo affect up to 30–40% of
the patients by middle age (5, 12).
DIAGNOSIS AND AUTOANTIBODY FINDINGS
The diagnosis of APECED is based on the clinical features,
detection of autoantibodies, and genetic analysis. Two of the
most common disease components are required for APECED
diagnosis. Candidiasis is usually the first symptom, while
hypoparathyroidism and Addison’s disease are the most common
endocrinopathies. Since the gene test is available, the diagnosis is
confirmed with the identification of the mutation. The type of
mutation, however, does not predict the disease course. Due to the
rarity of APECED, there is often delay of years before the diagnosis
is set (13).
An important feature in the diagnostics is the existence of
IgG autoantibodies. Their possible pathogenetic role is mostly
unknown. Many autoantibodies in APECED are targeted against
intracellular enzymes (14). It is possible that the detected autoanti-
bodies are not pathogenetic but, instead, are a marker of the ongo-
ing T cell activity at the target tissue (14). The presence of autoanti-
bodies correlates with the disease components but autoantibodies
can also precede the onset of the target organ failure (15). Some
autoantibodies are closely associated with the corresponding dis-
ease manifestation, while others are found only in a subset of
patients with the particular manifestation. For example, autoan-
tibodies against calcium-sensing receptor are found in almost all
APECED patients with hypoparathyroidism, whereas anti-NALP5
antibodies, also linked to hypoparathyroidism, are much less com-
mon (16, 17). Also, autoantibodies found in APECED patients
may be different from those found in patients with an isolated
autoimmune disease. A case in point is GAD (glutamic acid
decarboxylase), an important autoantigen in type I diabetes but
rarely targeted in APECED patients with diabetes as a disease
component (18).
Once the initial diagnosis is made, APECED patients must
be evaluated regularly and tested for autoantibodies, since new
disease components appear through life (19). Suggestions for lab-
oratory testing in the follow-up of APECED patients are presented
in Table 1.
The recently discovered neutralizing antibodies against type I
interferons are found in 100% APECED patients (20, 21). Anti-
interferon antibodies are present before symptom development at
high titers. In addition to APECED, type I interferon autoantibod-
ies have been found only in patients with thymoma, but with lower
prevalence and titers (20, 21). Thus, measurement of neutralizing
Table 1 | Suggested tests in suspected APECED and for the follow-up
of APECED patients.
Disease component Autoantibody Other tests
APECED Interferon-α and/or
interferon-ω
Hyperparathyroidism NALP5 Plasma calcium
Calsium-sensing receptor Plasma phosphate
Addison’s disease 21-hydroxylase Plasma renin
Adrenocortical antibodies Plasma ACTH
Diabetes mellitus type I IA-2
Hypothyroidism Thyroid peroxidase
Gonadal insufficiency Steroid cell antibodies FSH, LH, estrogen
Gastritis Parietal cell antibodies vitamin B12
Hepatitis LKM antibodies ALAT
In diagnosed APECED patients the aim is to screen for new disease components
for early diagnosis.
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antibodies against the type I interferons α and ω is a sensitive
diagnostic test.
Chronic mucocutaneous candidiasis correlates with autoanti-
bodies against Th17 class cytokines, both in APECED patients and
CMC patients without APECED (22–24). The autoantibodies are
neutralizing and have been found against IL-22 (91% of patients),
IL-17F (75%), and IL-17A (41%) (22). Testing for these antibod-
ies is not commonly used in the diagnostic evaluation, since the
abovementioned type I interferon antibodies are more prevalent
and specific.
NACHT leucine-rich-repeat protein 5 (NALP5) is a protein
expressed in the cytoplasm of parathyroid chief cells. Forty-nine
percent of APECED patients with hypoparathyroidism are posi-
tive for NALP5 antibodies (16). These antibodies are not found
in APECED patients without hypoparathyroidism or in non-
APECED patients with hypoparathyroidism. NALP5 antibodies
thus represent APECED-specific autoantibodies.
Adrenocortical autoantibodies can be detected by indirect
immunofluorescence assays. These antibodies recognize 21-
hydroxylase, 17-hydroxylase, and side-chain cleavage enzymes,
which are involved in the steroid hormone synthesis (11). Ovarian
insufficiency correlates with the presence of autoantibodies against
side-chain cleavage enzyme (11). Steroid cell autoantibodies can be
screened for by indirect immunofluorescence assays with ovarian
and testicular tissues. APECED patients with ovarian insufficiency
also have elevated FSH and LH levels and low estrogen levels (1).
Fifty percent of APECED patients with hepatic involve-
ment have liver-kidney microsomal (LKM) antibodies (25). The
cytochrome target antigen is CYP1A2. Autoantibodies against
CYP1A2 are highly specific (100%) but their sensitivity is only
50% (12). Plasma alanine amino transferase (ALAT) are a good
marker for developing autoimmune hepatitis in APECED (1).
Smooth muscle cell antibodies, which are a marker for autoim-
mune hepatitis, are not commonly present in APECED-associated
hepatitis (25).
In APECED,autoantibodies against IA-2 (tyrosine phosphatase-
like protein IA-2) correlate with the development of type I dia-
betes. However, the sensitivity is low (11). GAD antibodies are
relatively common (33%) in APECED patients but their pres-
ence does not correlate with diabetes, in contrast to non-APECED
patients (11, 18).
Gastrointestinal symptoms, for example constipation and diar-
rhea are common among APECED patients. Hypocalcemia due
to hypoparathyroidism can cause diarrhea. Exocrine pancreatic
failure occurs in a few percent of patients and can present with mal-
absorption and steatorrhea (9). Plasma calcium levels and exocrine
pancreatic function should be assayed in APECED patients with
diarrhea.
GENETICS OF APECED
Autoimmune polyendocrinopathy-candidiasis-ectodermal dys-
trophy is caused by loss-of-function mutations in the AIRE gene.
The human AIRE gene is found in the q22 region of chromosome
22, and shares a 71% sequence homology with its murine counter-
part Aire (3, 4, 26). At full length, AIRE encodes a 58 kDa protein
of 545 amino acids, although two other, shorter splice variants of
unknown significance have been described (4, 27). AIRE contains
a N-terminal caspase-recruitment domain and SAND domain
that together regulate AIRE’s multimerization, two plant home-
odomains (PHDs), and a proline-rich region (Figure 1) (28, 29).
The N-terminus also contains a nuclear localization signal, while
C-terminus is important for transcriptional activation. PHDs are
zinc fingers involved in protein-protein interaction, and PHD1 has
been shown to mediate the binding of AIRE to non-methylated
histone H3 (30–34). Together, these sequence and structural fea-
tures suggest a role in the regulation of gene transcription, but
despite some data suggesting otherwise (35), it is unlikely that
AIRE is a transcription factor that directly binds DNA.
Today, more than 60 APECED mutations have been identified.
The mutations are found throughout the coding region in AIRE
and include nonsense mutations causing premature stop codons,
frameshifts caused by deletions and missense mutations (36). The
most common ones are the mutations R257X (c.769C>T) in exon
6 and a 13-base pair deletion (c.967–979del) in exon 8 (37, 38).
APECED is inherited in an autosomal recessive manner and het-
erozygosity does not cause APECED. However, there is one Italian
family where a dominantly inherited mutation in the AIRE gene
(G228W) causes APECED (39).
In general, the type of mutation in APECED does not cor-
relate with the clinical features (40). Phenotype can vary even
between siblings carrying the same mutation (9). However, the
R257X mutation carriers have more commonly candidiasis than
patients with other mutations (40). Also, Iranian Jews APECED
patients have a unique mutation (Y85C, c.374A>G) and do not
develop keratopathy or candidiasis (10).
AIRE’s EXPRESSION AND FUNCTION
A few years after the discovery of the genetic defect responsible
for APECED, experiments with knockout mouse models linked
AIRE to the transcription of tissue-restricted antigens (TRAs) in
thymus. The highest expression of AIRE is found in medullary
thymic epithelial cells (mTECs) (41), which are capable of express-
ing a diverse set of genes normally restricted to certain tissues
(42, 43). This phenomenon has been denoted ectopic transcrip-
tion and is likely to be important for the deletion of autoreactive
thymocytes. In the absence of Aire a subset of thymic TRAs was
FIGURE 1 |The structure of AIRE protein. CARD: caspase recruitment
domain; SAND: human Sp100, Aire1, NucP41/P75, and Drosophila DEARF1
domain; PHD: plant homeodomain; PRR: proline-rich region. CARD and
SAND are associated with AIRE multimerization and nuclear localization,
while PHD1 mediates binding to non-methylated histone H3. Mutations
disrupting AIRE’s function have been found in all domains except PRR, and
also at the extreme C-terminus. Areas where recessive mutations have
been found are shown below the schematic structure as horizontal lines,
while the location of the dominant mutation is shown as a vertical line.
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down-regulated, suggesting that Aire functioned as a regulator of
the ectopic transcription of some TRAs in mTECs (44). Another
study using a model antigen with Aire-regulated promoter pro-
vided evidence of increased development of autoreactive T cells
and subsequent autoimmunity when Aire was knocked out, at least
in that particular transgenic system (45). Later studies have con-
firmed but also complicated the link between TRA transcription
and Aire (2).
It has been difficult to establish how AIRE facilitates TRA tran-
scription, given the promiscuous nature of its function and the
diverse and context-dependent set of genes affected by AIRE’s
absence. Several studies have reported that AIRE can bind DNA,
suggesting that it might function as a transcription factor (35, 46).
Others, however, have challenged the significance of direct DNA
binding by AIRE (32, 47, 48). Moreover, the genes regulated by
AIRE lack shared promoter elements (47), and it is thus difficult
to see how AIRE could by direct DNA binding regulate such a
diverse set of genes.
A detailed analysis of AIRE’s molecular partners suggests a less
direct role for AIRE in gene transcription. A common feature of
AIRE-regulated genes is that they are associated with a stalled
RNA polymerase II (RNAPII), which stops full-length transcrip-
tion (34, 49, 50). AIRE then seems to allow further elongation
of the target genes. A recent attempt to formulate a model sug-
gests that AIRE first binds to non-methylated histone H3 (29). It
then recruits positive transcription elongation factor b (P-TEFb)
to phosphorylate RNAPII, reactivating the stalled polymerase and
gene transcription. Although this would allow for a broad range of
genes to be activated, a major problem with this model is to explain
how AIRE’s control on TRAs is maintained even when the TRAs
are expressed as transgenes, outside of their normal epigenetic
environment.
A competing explanation is that AIRE is not directly involved
in TRA transcription, but rather regulates mTEC maturation and
death, thus indirectly affecting also mTEC-expressed TRAs. In
support of this possibility are numerous studies showing that Aire-
deficiency results in fundamental changes in the mTEC population
(51–54). The expression of AIRE is a late event in the lifespan of
mTECs (55), and it has been suggested to be a terminal differenti-
ation factor for mTECs. Thus, in the absence of AIRE, the altered
developmental pathway of mTECs might lead to a decrease in the
TRA-expressing stages, either because of abnormal cell death or
diverted or arrested maturation. However, although the mTEC
differentiation model is compatible with most reported effects
of AIRE-deficiency, the molecular mechanisms by which AIRE
regulates mTEC biology are largely unknown.
The strengths and weaknesses of scenarios involving regula-
tion of gene transcription versus regulation of mTEC homeostasis
have been more fully summarized in a recent review (47). At the
moment the available data do not provide unequivocal support to
either of the two main models, and it should also be noted that
practically all the data come from studies on the murine system
or cell lines. Nevertheless, we would argue that the human phe-
notype is difficult to reconcile with models invoking regulation of
TRA transcription as the main function of AIRE. We discuss these
aspects in more detail below, in the chapter on the pathogenesis of
APECED.
A further complication is AIRE’s expression in peripheral tis-
sues, a phenomenon of largely unknown significance (56). Early
studies showed AIRE mRNA expression in a wide range of tissues,
but not all of these studies were confirmed on protein level. In the
periphery AIRE is expressed at significantly lower levels than in the
mTECs, making reliable detection with mostly polyclonal antibod-
ies difficult, and some studies have questioned the presence of any
extrathymic AIRE (57). Nevertheless, a wide agreement exists for
the expression of AIRE in lymphoid tissues, with perhaps den-
dritic cells as the main AIRE+ population (58, 59). The peripheral
AIRE+ cells can also express TRAs, although the genes are only
partly overlapping with the thymic set (60).
IMMUNOLOGICAL ABNORMALITIES
The most obvious immunopathological finding in APECED
patients is the diverse set of autoantibodies, mostly against tis-
sues affected by the disease. The autoantibodies are often directed
against enzymes involved in hormone synthesis, but since these
enzymes are intracellular, the organ-specific autoantibodies rarely
have pathogenetic significance. Of special interest are the neu-
tralizing autoantibodies to cytokines, since they are likely to have
pathogenetic effects. These autoantibodies are found in practi-
cally all APECED patients, while extremely rare in healthy people,
and can block interferon-induced gene expression both in vivo and
in vitro (21, 61). The more recently described neutralizing autoan-
tibodies against the Th17 cytokines IL-17A, IL-17F, and IL-22 are
linked to the defective antifungal defense and CMC (22, 24).
However, the organ-specific autoimmune manifestations of
APECED are generally held to be T cell-mediated, and therefore
the T cell compartment in APECED patients has been studied in a
number of studies. A recent study showed that APECED patients
have a significantly increased frequency of highly differentiated
CD8+ effector T cells (62). These cells express CD45RA and lack
CCR7, a phenotype similar to that found in some chronic viral
infections, and express cytotoxic molecules, such as perforin. The
specificity of these cells is not known, but it is likely that at least
some of them represent the autoreactive population.
The CD4+ population likewise shows changes, but so far the
data are scant and partly contradictory. An increased frequency of
CD25+CD4+ cells, including both regulatory and activated pop-
ulations, was reported in one series of patients (63), while a later
study failed to find differences between patients and controls in
the frequency or number of CD4+ activated/memory T cells (64).
With the discovery of anti-cytokine antibodies the cells produc-
ing Th17 cytokines have also been studied. Despite the presence
of anti-IL17 antibodies, IL-17A production is generally normal or
even increased, while IL-17F is reduced. An even greater reduction
is found in IL-22 responses (22, 65, 66). These defects are closely
linked to the chronic candidiasis.
The best-defined T cell defects, confirmed by several studies, are
found in the regulatory T cell (Treg) population. The earliest report
showed that APECED patients have a decrease of CD25+CD4+
Tregs, a finding later confirmed in another cohort (64, 67). A more
detailed examination was facilitated by the discovery of FOXP3 as
the key transcription factor in Tregs, and subsequent development
of mAb allowing the identification of FOXP3+ cells. APECED
patients have a decreased frequency and number of FOXP3+Tregs,
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and in a single-cell analysis the Treg cells express reduced levels of
FOXP3 protein (68). Moreover, in an in vitro co-culture assay
Tregs isolated from APECED patients show defective suppressive
function. The most clear-cut Treg abnormalities are found in the
CD45RO+ activated subset, the population mostly responsible for
the regulatory activity (62, 69). Cells of the innate immune sys-
tem have also been analyzed, especially those in which AIRE is
expressed. The frequency of circulating dendritic cells has been
reported to be normal (64, 70), but several studies suggest func-
tional changes, at least in monocyte-derived dendritic cells (58,
71, 72). However, here again the published results have been partly
conflicting, with some reporting hyperactivation of dendritic cells,
and others defective cytokine production and functional impair-
ment. The expression of pattern-recognition receptors has also
been studied and seems normal (70).
An altogether different putative role for AIRE links it with
Dectin-1, a receptor of the innate immune system (73). AIRE
was reported to form transient complexes with Dectin-1 path-
way components and localize with Dectin-1 at the cell mem-
brane. In APECED patients peripheral blood mononuclear cells
the production of TNF-α in response to Dectin-1 ligation was
reduced. Because Dectin-1 is important in innate recognition of
β-glucan and anti-Candida responses, these findings offer an alter-
native mechanism for the defective antifungal defense in APECED
patients.
With the exception of the increased susceptibility to Candida,
the general view emerging from these studies, perhaps not unex-
pectedly, is one of increased effector activity and decreased regu-
lation. As in all human studies, two major problems complicate
the interpretation of these results. First, the analysis is restricted to
circulating cells, which are likely to be at best a partial reflection of
the local autoimmune process. Secondly, most of the studies have
been performed on adult patients with long-established disease,
and care is needed to separate primary pathogenetic factors from
secondary effects of the disease process. We will discuss pathogen-
esis below. Nevertheless, it is also important to note that not all
secondary processes are irrelevant to the pathogenesis. In most
patients, new targets of autoimmunity and new disease mani-
festations continue to appear later in life, and it is likely that
the general immune dysregulation is a contributing factor in this
unpredictable progression of the disease.
PATHOGENESIS
Given the expression pattern of AIRE, it is highly likely that the
thymus is in a central role in the pathogenesis of APECED. The
simplest putative explanation for the disease is based on the link
between AIRE and ectopic transcription of TRAs in the thymus.
In this model the absence of AIRE-regulated TRAs in the thymus
disrupts negative selection and allows the escape of autoreactive
T cells to periphery, which leads to organ-specific autoimmunity
(Figure 2). Support for this scenario comes from murine studies,
and in particular transgenic settings with Aire-regulated model
antigens (44, 45, 74, 75).
However, several aspects of both the murine and human AIRE-
deficient phenotype are very difficult to reconcile with this simple
model. A corollary of TRA-driven autoimmunity is that at least
the earliest events should be specific to AIRE-regulated TRAs and
FIGURE 2 | A hypothesis of the pathogenesis of APECED. In the normal
thymus mTECs express a range of tissue-restricted antigens, shown here
as red and green circles within the mTECs. This facilitates the deletion of
autoreactive thymocytes, shown as cells with a red or green TCR, so that
only T cells reactive to non-self antigens migrate to the periphery. The
normal thymus also supports the development of regulatory T cells (Tr). In
the absence of functional AIRE the epithelial compartment is disrupted, as
indicated by the malformed mTEC, and some of the TRAs are no longer
transcribed. Thymocytes specific to these TRAs mature in increased
numbers. They may also become activated already in the thymus, shown
here as an increase in cytoplasm volume, so that the thymus exports
functional effector cells. At the same time the development of Tr cells is
defective, leading to insufficient suppression in the periphery. The outcome
is organ-specific autoimmunity, at least partly directed by the range of TRAs
missing in the AIRE-deficient thymus (here indicated by the red tissue).
the response limited to clones that escaped negative selection. In
the murine system some of the reported manifestations involve
antigens that are independent of AIRE, suggesting that loss of
TRAs is not an obligatory prerequisite of the autoimmunity (76).
In humans, perhaps the main problem for the TRA model is to
explain the early and universal incidence of anti-interferon anti-
bodies. As noted earlier, these antibodies can precede any clinical
symptoms or organ-specific autoantibodies (5), strongly suggest-
ing that their appearance is an important part of the pathogenetic
process, or at least reflects it. It is very difficult to see how, without
any additional defects, the loss of TRAs in mTECs alone could give
rise to this particular phenomenon. Another difficulty arises from
the study of thymomas. The disorganized thymoma tissue often
lacks AIRE expression, yet continues to support T cell matura-
tion. If the loss of TRAs and subsequent escape of autoreactive
T cells would suffice to cause APECED, a substantial fraction
of thymoma patients should develop it. Yet the patients rarely
show APECED-like manifestations (77, 78). Instead, autoimmu-
nity associated with thymomas is dominated by myasthenia gravis,
which conversely is not a manifestation of APECED (9, 79).
An alternative model suggests that the loss of AIRE leads to a
more extensive disruption of the thymic microenvironment, creat-
ing conditions that favor activation instead of tolerance. Although
a primary lymphoid organ, thymus is also capable of developing
tertiary lymphoid organization, with germinal centers and induc-
tion of adaptive immunity (5). The unique feature of thymus is
that, unlike in the secondary lymphoid organs, many of the T cells
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inhabiting the organ have not yet passed negative selection and are
potentially highly autoreactive. The crucial difference when com-
pared with the TRA model is that here the thymus would export
preactivated autoreactive T cells, perhaps in high numbers, and
not naive, clonally restricted autoreactive precursors. Moreover,
since the absence of AIRE is also likely to disrupt the develop-
ment of natural Tregs (80–82), the defect in immunoregulatory
mechanisms contributes to the emerging autoimmunity.
Several observations support the view that a more wide-
spread thymus disturbance than decreased TRA expression alone
is responsible for APECED. First, thymoma patients also develop
anti-interferon antibodies (83), a feature shared only by these two
diseases affecting the thymus, and resected thymoma tissue often
shows tertiary lymphoid structures (79, 84). Secondly, in APECED
patients even cells expressing markers typical of naive lympho-
cytes, e.g., CD45RA and CCR7, show clear signs of functional
activation, such as the expression of perforin (62). Interestingly,
this also applies to CD8+ T cells expressing CD31, a marker of
recent thymic emigrants (RTEs). This is consistent with activat-
ing events taking place already in the thymus, so that the cells
migrate to the periphery preactivated. Similarly, the CD31+ sub-
set among resting Tregs is clearly abnormal, suggesting that the
Treg cell defect is also traceable to the thymic development (80).
And thirdly, indirect support is provided by the studies showing
disruption of thymic medulla in the absence of functional Aire. A
dysregulated thymus functioning as an induction site for autoim-
mune responses would also explain the relatively early onset of the
disease.
Nevertheless, the fact that most patients develop similar main
components of the disease suggests that the initiation of autoim-
munity does show predilection to certain self antigens. It is there-
fore likely that the range of TRAs missing from the AIRE-deficient
thymus, whether primarily due to transcriptional failure or dis-
rupted mTEC development, defines at least to some extent which
peripheral organs are targeted. The early pathogenetic events in
the thymus would thus be a combination of a general failure to
imprint tolerance and a clonally restricted targeting of a subset of
potential self antigens.
This thymus-centered view on the pathogenesis of APECED
leaves important questions open, including the significance of
peripheral AIRE. So far, this is issue is largely unknown, apart from
what can be extrapolated from murine studies and the observed
changes in the characteristics of dendritic cells and other AIRE+
peripheral cells when AIRE is absent. Likewise, AIRE’s interac-
tion with Dectin-1 partners and its contribution to the antifungal
defense remains to be defined.
Moreover, the disease manifestations traditionally held to
be caused by factors other than autoimmunity need to be re-
examined. The recent data on neutralizing antibodies against
Th17 cytokines, and on the importance of these cytokines in anti-
Candida defense strongly suggests that the chronic candidiasis is
basically an autoimmune phenomenon, too (7). It may also be
questioned whether the ectodermal disease components represent
developmental dystrophies, as was originally believed. The argu-
ment against this view holds that since they are not congenital
but develop later, a primary defect is unlikely. However, with the
exception of such clearly autoimmune manifestations as alopecia
and vitiligo, the pathogenesis of ectodermal components is still
unknown.
AIRE IN OTHER DISEASES
Because the effects of AIRE-deficiency are so drastic, many stud-
ies have addressed the possibility that heterozygous mutations or
genetic variants of AIRE might also predispose to autoimmu-
nity. So far, the results are intriguing but inconclusive and to
some extent contradictory. Studies on the first-degree relatives
of APECED patients have generally failed to find a link between
heterozygous carriage of AIRE mutations and autoimmune dis-
eases (85, 86), although some data suggesting otherwise have been
reported (87). A clear limitation in all such studies is the small
number of study subjects. Another approach has been to search
for AIRE mutations in patients with isolated autoimmune diseases.
In most cases heterozygotes have not been found to be enriched
among the patients (88, 89), but again there are some conflicting
data (90). However, several recent studies suggest that single-
nucleotide polymorphisms in the AIRE gene are associated with
an increased risk of autoimmunity, including rheumatoid arthri-
tis and vitiligo (91–93). It is therefore probable that more detailed
analysis of AIRE will reveal more instances in which genetic vari-
ation in AIRE, presumably leading to modulation of its function,
affects the predisposition to non-APECED autoimmunity.
CONCLUDING REMARKS
Despite the simple genetics of AIRE, the resulting phenotype is
highly complex, and the disease manifestations can vary greatly
between patients with identical mutations. The significance of
this complexity has sometimes been dismissed by attributing it
to secondary effects of a longstanding disease or the genetic het-
erogeneity of the patients. Although both arguments are relevant,
they can also be a too facile way to sidestep important issues.
The simple model of reduced TRA expression as the main mech-
anism of APECED is increasingly untenable, so alternative and
additional mechanisms must be considered, and human patients
studied to test them. Moreover, although the genetic diversity
of the human patients certainly influences and complicates mat-
ters, it must be accepted and addressed. The relative simplicity of
inbred Aire-deficient animal models is attractive but also poten-
tially deceptive. After all, in the end the results have to be taken
back to human patients, when the outbred nature of the subjects
is an unavoidable fact.
The existing data indicate that the earliest pathogenetic events
leading to APECED take place in the thymus, and it is very likely
that a general disturbance of mTEC population is involved. The
associated disruption of TRA expression, whatever its exact mech-
anism, is likely to limit the targets of the resulting autoimmunity,
but perhaps not the later appearance of additional, less com-
mon disease components. Some of the disease manifestations
may also reflect the failure of peripheral tolerance, although the
significance of peripheral AIRE expression remains poorly under-
stood. Because the relevant tissues cannot be accessed in APECED
patients, many of the open questions can be addressed only indi-
rectly. In particular, innovative organ culture methods to analyze
the role of AIRE in the human thymus are likely to provide a means
to test the proposed pathogenetic pathways.
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